Endocrine tumors - clinical and preclinical studies

DNA microarray analysis

Molecular genetic analysis of endocrine tumors (thyroid, parathyroid, adrenal, neuroendocrine): pathogenesis and development of metastases.

Preclinical research

The aim of these projects are

The aim of these projects are to elucidate the genetic mechanisms that are driving the development of endocrine tumors (thyroid, parathyroid, adrenal, neuroendocrine).


Many tumors are caused by genetic changes. The majority of tumors are thought to be sporadic and in these cases caused by somatic mutations. Some tumors, however, are hereditary and caused by germline mutations. With regard to tumors of the adrenal medulla (pheochromocytomas), it was thought for many decades that about 10% are hereditary caused by mutations in one of 3 genes (NF1, VHL, RET).

This changed in 2000 when another hereditary form was identified. Mutations in a new gene (SDHD) were found. These mutations were first found in paragangliomas (=extra-adrenal pheochromocytomas) but in the same year even in pheochromcytomas (Gimm et al., Cancer Res 2000). These days, it is known that more than 17 genes contribute to at least 30% hereditary pheochromocytomas.

More and more is also known regarding the genetic driver events in sporadic pheochromocytomas. We and others found that NF1 is the most commonly mutated gene (Welander et al., Hum Mol Genet 2012).


We started with the identification of chromosomal regions with loss or gain (picture at the top, DNA microarray analysis). We then added various methods to look for mutations (including whole-exome sequencing) and analyzed gene expression (including microarray chip analysis). We have identified various interesting genes that are currently under further investigation (including functional analysis using cell lines).

Clinical research


The aim of these projects is to improve our ability to localize small endocrine tumors (e.g., ectopic parathyroid glands) either by modifying existing techniques or by developing new techniques.


Tumors less than 0.5-1 cm in diameter are hard to localize with existing imaging techniques. Tumor metastases are often smaller than this. When it comes to endocrine tumors, even benign tumors such as parathyroid adenomas can be small but still cause problems due to the increased hormone production.

Here, it would be desirable to develop better localizing techniques that may even be used to develop new localization techniques concerning malignant tumors. Eventually, even the development of new treatment modalities is conceivable.


Concerning parathyroid adenomas, we have modified a well known radiological technique called selective venous sampling (picture below left, sSVS_DECT). Here, in a second step, the region with the highest parathyroid hormone after the first round of venous sampling is investigated, narrowing the area of interest (Gimm et al., Surg Today 2012).

We have also used a relatively new technique called dual-energy computed tomography (DECT) to localize parathyroid tumors (picture below right, sSVS_DECT) that were missed by other imaging techniques (Gimm et al., JCEM 2010).

Currently, we are collaborating with professor Kajsa Uvdal and professor Anders Persson in order to develop new more sophisticated imaging methods.


Superselective venous - CT

Left: Superselective venous sampling of parathyroid hormone (PTH) levels helping regionalizing a parathyroid adenoma responsible for hypercalcemia

Wright: Dual-energy CT localizing an ectopic parathyroid adenoma missed by other imaging techniques

Research Group

Research Area